



FOR IMMEDIATE RELEASE: 09:00 MONDAY 17 NOVEMBER

Information for Investors

CNX Therapeutics commences production of Sumatriptan Alginate Film as launch preparations advance

London, England - Monday 17 November: CNX Therapeutics Limited ("CNX Therapeutics"), a European specialty pharmaceutical company, today announced that production has commenced for Sumatriptan Alginate Film, marking a significant milestone in the company's preparations to bring this new migraine treatment to European markets.

Following the strategic licensing agreement announced with Klaria in January 2025, CNX Therapeutics is now actively progressing towards commercial launch, with production underway to ensure supply readiness. The company is finalising its commercial strategy, including brand naming and market positioning, which will be announced in due course.

Sumatriptan Alginate Film offers a meaningful alternative to traditional migraine treatments such as tablets, nasal sprays and injections. The postage stamp-sized film is delivered orally, providing a bioequivalent dose of sumatriptan, making it an appropriate option for patients who struggle with other forms of medication.

The product received regulatory approval in August 2024 for key European markets including Germany, Spain and Italy. CNX Therapeutics is working towards making the treatment available in pharmacy & other healthcare settings across Europe, with further details on launch timing and market rollout to be communicated later this year.

"We're pleased to reach this important milestone with Sumatriptan Alginate Film", **said Emma Bush, VP Commercial at CNX Therapeutics.** "This progress reflects our commitment to expanding patient access across Europe, and we look forward to the next steps as we move closer to launch."

Fredrik Hübinette, Chairman of the Board and Co-Founder of Klaria, added: "It's excellent to see this product advancing into production. This milestone represents meaningful progress in our partnership with CNX Therapeutics, and we are looking forward to bringing this treatment option to patients."

This development reinforces CNX Therapeutics' commitment to expanding access to new CNS treatments and strengthening its pan-European portfolio.

ENDS

Notes to editors

For more information, please contact Mehdi Juma, CNX Communications Manager:
mehdi.juma@cnx-therapeutics.com

About Sumatriptan Alginate Film:

Sumatriptan Alginate Film (SAF) is a product designed to address a key unmet medical need in the treatment of migraine. SAF is bioequivalent to the nasal spray and can also be used instead of tablets or injections. SAF is an alginate-based oral trans-mucosal film and is the first oral trans-mucosal migraine product available for acute migraine treatments, particularly suitable for patients suffering from migraine-induced nausea and vomiting. Information about the licensing agreement, announced in January 2025, can be found [here](#).

About CNX Therapeutics:

CNX Therapeutics is a speciality pharmaceutical company committed to improving the lives of patients by providing access to essential medicines. CNX commercialises and distributes a portfolio of pharmaceuticals for neurological, psychiatric and hospital emergencies in over 60 markets worldwide, both directly and through strategic partnerships, and is an attractive partner for companies who are looking for a pan-European partner for Central Nervous System (CNS) and hospital injectable products, which is committed to the highest standards of ethics and sustainability. For more information, visit: www.cnx-therapeutics.com

About Klaria Pharma Holding AB:

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, fast-acting products. By combining a patented technology – a film that adheres to the oral mucosa – with well-proven substances, the company has developed a concept for drug distribution with many advantages and potential uses. Klaria is listed on the First North Growth Market under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, 08-528 00 399) for Klaria Pharma Holding AB.